Sermorelin
Sermorelin acetate; GHRH(1-29); GRF(1-29); Geref; Geref Diagnostic
The Ground Truth Score
four plain questions, never one numberReal ex-FDA drug; thin modern adult data
Bottom line
Sermorelin is a genuinely well-characterized, formerly FDA-approved GHRH fragment with a strong pediatric and diagnostic pedigree, but the modern adult "anti-aging" use rests on a handful of small, mostly open-label studies and is off-label, compounded, and not FDA-approved for that purpose.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Commonly reported off-label adult dosing is roughly 100-300 mcg subcutaneously once daily, typically titrated; some protocols use ~200-500 mcg.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Human use dates to GHRH(1-29) research in the early-to-mid 1980s following the 1982 characterization of growth-hormone-releasing hormone; sermorelin acetate was studied in humans as a GH secretagogue and pituitary-stimulation diagnostic through the late 1980s and was FDA-approved as Geref in the 1990s (pediatric GH-deficiency treatment) and as Geref Diagnostic for the GH stimulation test. Unlike most gray-market peptides, sermorelin DOES have completed, registrational human trials, but those supported pediatric/diagnostic use, NOT adult anti-aging, body composition, or sleep, for which the controlled human evidence remains thin.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- A 29-amino-acid fragment of endogenous GHRH that prompts the pituitary to release its own growth hormone in pulses, rather than injecting GH directly.
- Because it works upstream and preserves pituitary feedback, proponents argue it carries a gentler, more physiologic profile than exogenous HGH.
- Small studies in older adults report rises in IGF-1, modest lean-mass gains, improved slow-wave sleep, and better self-reported well-being and libido.
- It is a former FDA-approved drug (Geref) with a known pharmacology and adverse-event profile, unusual for this category.
- Modern adult use is off-label and supplied by 503A/503B compounding pharmacies; it remained on the permitted-compounding side of the FDA's April 2026 peptide reshuffle.
The data behind each bullet
What actually backs it
Sermorelin is a synthetic analog of the first 29 amino acids of human GHRH (the biologically active fragment) and stimulates pituitary GH secretion without materially altering prolactin, LH, FSH, insulin, cortisol, glucose, or thyroid hormones.
Well-established pharmacology from the FDA-era Geref/Geref Diagnostic label and multiple GHRH physiology studies; this is the mechanistic basis of the approved diagnostic GH-stimulation test.
PubMed: sermorelin GHRH 1-29 growth hormone secretion ↗Sermorelin reliably raises GH and IGF-1 in adults; reported IGF-1 increases are on the order of ~20-30% in small studies.
Demonstrated in small adult/elderly studies (e.g., Corpas, Vittone/Khorram-type nightly-injection cohorts), real human data but small samples, mostly open-label or short-duration, not large blinded RCTs.
PubMed: sermorelin IGF-1 elderly older adults ↗In healthy older adults, nightly sermorelin produced modest lean-body-mass gains (~1.2-1.3 kg in men), increased skin thickness, improved insulin sensitivity, and increased self-reported well-being and libido over ~16 weeks.
Small prospective study in elderly subjects (roughly a dozen participants, ~16 weeks); informative but underpowered, short, and not placebo-controlled for the subjective endpoints.
PubMed: sermorelin elderly lean body mass skin thickness ↗GHRH/GH administration enhances slow-wave (deep) sleep and reduces awakenings, the plausible basis for the 'better sleep' reports.
Supported by controlled human sleep-EEG studies of GHRH and GH on slow-wave sleep, though sermorelin-specific, blinded sleep RCTs in healthy adults are limited.
PubMed: GHRH slow wave sleep humans ↗Sermorelin was FDA-approved (Geref / Geref Diagnostic) for pediatric GH-deficiency treatment and as a GH-stimulation diagnostic, then voluntarily withdrawn from the US market in 2008 for commercial reasons, not safety or efficacy.
FDA approval history and 2008 commercial discontinuation are documented in FDA records and the Federal Register discontinuation notices.
FDA Drugs@FDA / DailyMed: sermorelin (Geref) ↗No large, modern, placebo-controlled RCT supports sermorelin for adult anti-aging, fat loss, or muscle gain; all current adult product is compounded (503A/503B), not FDA-approved for those uses.
Absence of registrational adult-indication trials; ClinicalTrials.gov shows only limited and mostly older or small studies. Modern use is off-label by physician prescription.
ClinicalTrials.gov: sermorelin ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Sermorelin is a truncated GHRH agonist (the active 1-29 fragment of growth-hormone-releasing hormone). It binds pituitary GHRH receptors on somatotrophs and stimulates synthesis and pulsatile release of the body's own growth hormone, which in turn raises hepatic IGF-1. Because it acts within the normal hypothalamic-pituitary feedback loop (downstream GH/IGF-1 and somatostatin still regulate output), it produces self-limited, pulsatile GH rather than the flat, supraphysiologic levels of injected HGH. For the approved diagnostic use the mechanism is established; for adult anti-aging benefits the downstream clinical mechanism is plausible but the magnitude of real-world benefit is the open question.
Dosing & handling
What users and clinicians report
Commonly reported off-label adult dosing is roughly 100-300 mcg subcutaneously once daily, typically titrated; some protocols use ~200-500 mcg. The original FDA diagnostic/treatment context used larger single doses (e.g., ~2 mg subcutaneous in adult studies). Frequently cycled (e.g., several months on, with breaks) in longevity practice. This is REPORTED community/clinic practice, not a prescription or endorsement.
All adult dosing here is reported practice, not medical advice and not an FDA-approved regimen. Dose-finding for healthy-adult longevity use has never been established in large trials, vial-labeled concentrations vary by compounding pharmacy, and any GH-axis stimulation should be done under a clinician who can monitor IGF-1 and glucose. Verify the actual vial concentration before doing any dose math.
Timing & food
Most commonly injected subcutaneously at bedtime on an empty stomach (roughly 2+ hours after eating, or fasted). The rationale: the largest natural GH pulse occurs in early deep sleep, so timing the dose to that window is meant to amplify the physiologic pulse, while food, especially carbohydrate/insulin and somatostatin tone after meals, blunts the GH response, so a fasted state preserves a cleaner GH spike.
Half-life
Short, approximately 11-12 minutes after intravenous or subcutaneous dosing; rapidly cleared (adult clearance ~2.4-2.8 L/min), with peak GH stimulation within minutes. The brevity is why it is dosed to coincide with the natural nocturnal GH pulse and why effects are pulsatile rather than sustained.
Reconstitution sensitivity
Sensitive. Lyophilized powder is stored frozen/cold and is stable for many months; once reconstituted (with bacteriostatic water, added gently down the vial wall and swirled, not shaken) it must be refrigerated at 2-8C and typically used within ~28 days (some pharmacies advise ~21). It degrades with heat excursions, light, and freezing of the reconstituted solution; reported potency loss can be meaningful within a day at room temperature, so it should not be left out and not re-frozen after mixing.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
High volume of reports. Sermorelin is one of the most widely prescribed/compounded peptides in US anti-aging and men's-health/telehealth practice, so community and clinic-patient reports are abundant relative to obscure gray-market peptides.
Consistency
Fairly consistent on a few themes, most notably deeper/better sleep within the first 1-2 weeks, and gradual improvements in recovery, body composition, and well-being over months. Consistency is weaker and more variable for dramatic fat-loss or muscle-gain claims, which many users say are subtle or require the accompanying diet/training/TRT to materialize.
Source credibility
Mixed-to-moderate. Much of the loudest 'benefit' messaging comes from clinics and vendors that profit from selling it, which warrants heavy discounting. However, the sleep and IGF-1 signals are corroborated by FDA-era pharmacology and small but real human studies, which raises credibility above the typical vendor-only peptide. Net: the anecdote is plausible and partly mechanism-backed, but still anecdote, not proof of meaningful anti-aging outcomes.
- Anecdotally, the single most common report is improved sleep depth/quality within the first one to two weeks, often the first thing users say they notice.
- Many describe a gradual sense of better recovery, energy, and well-being over 1-3 months rather than any dramatic overnight change, with some reporting improved libido.
- Body-composition reports (slightly leaner, modest muscle/skin improvements) are common but usually described as subtle and entangled with concurrent diet, training, or TRT, many users concede they can't cleanly separate sermorelin's contribution.
- The most frequently reported downside is transient injection-site irritation, flushing, or headache early on, plus complaints about handling hassle (refrigeration, short reconstituted shelf life) and variable results between compounding-pharmacy batches.
Placebo risk, Moderate
Moderate. Some endpoints are objective and measurable (IGF-1, GH, lean mass, skin thickness, insulin sensitivity), which anchors part of the effect in real physiology. But the headline benefits people chase and report, better sleep 'feel,' energy, recovery, mood, libido, well-being, are largely subjective, were often measured open-label, and ride on simultaneous lifestyle/TRT changes, so a meaningful share of perceived benefit could be expectancy or confounding.
Risk panel
What could go wrong
Adverse events
Best-characterized adverse event is a local injection-site reaction (pain, redness, swelling) in roughly 1 in 6 patients. Systemic effects in fewer than ~5% include facial flushing, headache, nausea/vomiting, dizziness, pallor, taste disturbance, and occasional mild joint pain, typically within the first ~30 minutes post-injection and often easing over the first week or two. This profile comes largely from the diagnostic/pediatric FDA-era label.
Theoretical concerns
Because it raises GH and IGF-1, the theoretical concerns mirror those of GH-axis stimulation: water retention/edema, carpal-tunnel-type symptoms, arthralgia, and insulin-resistance/glucose effects at higher exposures. The most-cited long-horizon worry for any IGF-1-raising agent is whether chronically elevated IGF-1 could promote growth of occult or existing malignancies; this is theoretical for sermorelin (it works within the pituitary feedback loop and produces pulsatile, self-limited GH) but is the reason it is contraindicated where active cancer is present.
Contraindications
Should be avoided with known or suspected active malignancy. Caution/contraindication with untreated hypothyroidism (blunts the GH response and the underlying condition needs treatment first), and with drugs/conditions that suppress the GH response (glucocorticoids). Not for use in pregnancy/breastfeeding. Genuine adult GH excess (e.g., acromegaly) is a contraindication. Effects can be blunted by obesity, hyperglycemia, and elevated somatostatin tone.
Honest unknowns
No long-term safety data exist for chronic adult use in healthy people seeking anti-aging or body-composition benefits, the original human safety database was built around short diagnostic exposures and pediatric treatment, not years of nightly self-injection. Compounded product quality (purity, potency, endotoxin) varies by pharmacy and is not held to NDA standards. The durability of benefits is uncertain: in the elderly data, IGF-1 elevation began declining by ~16 weeks, hinting at tachyphylaxis/adaptation over time.
Confound watch
Adult sermorelin users very frequently stack it, which heavily muddies attribution: testosterone/TRT (independently improves body composition, libido, and well-being), other GH secretagogues (CJC-1295, ipamorelin, tesamorelin), GLP-1 agonists (semaglutide/tirzepatide for fat loss), and aggressive diet/training and sleep-hygiene changes started at the same time. Better sleep alone can drive much of the reported 'recovery,' 'mood,' and 'body comp' improvement. Most clinics also start it alongside a broader 'optimization' protocol, so single-agent effects are rarely isolable.
History
Discovery → first use → status
- 1982GHRH is isolated and characterized; its first 29 amino acids are identified as the biologically active core, setting up sermorelin (GHRH 1-29).
- Mid-1980sSermorelin acetate studied in humans as a GH secretagogue and as a pituitary GH-stimulation diagnostic agent.
- 1990sFDA approves Geref (sermorelin) for treatment of idiopathic GH deficiency / growth failure in children, and Geref Diagnostic for the GH-stimulation test.
- 2008Sermorelin (Geref) voluntarily withdrawn from the US market for commercial reasons, not safety or efficacy.
- 2010s-2020sResurfaces via 503A/503B compounding pharmacies for off-label adult anti-aging, body-composition, and sleep use; becomes one of the most widely compounded peptides in the US.
- Apr 2026In the FDA's peptide 503A Category-2 reshuffle, sermorelin remains on the permitted-compounding side (not among the substances removed), while many gray-market peptides were restricted.
Verification
The COA standard, applied
Cross-checked across the FDA-era Geref pharmacology (mechanism, half-life, adverse events), independent regulatory/legal summaries of the 1990s approval and 2008 commercial withdrawal, the FDA April 2026 503A peptide list, and small adult/elderly human studies (Corpas; Vittone/Khorram-type nightly-injection cohorts) for IGF-1, lean mass, skin thickness, sleep, and libido endpoints. Where vendor pages and clinic blogs agreed with the FDA-label-derived facts (half-life ~11-12 min, injection-site reactions, GH/IGF-1 rise), those were treated as reliable; subjective-benefit and dosing claims from vendors/clinics were discounted as anecdote/practice and graded down. The 1990 vs 1997 approval-year discrepancy across secondary sources was noted and the entry left framed as 'the 1990s' rather than asserting a single unverified year.
The full verification standard →Sources
Where this comes from
- FDA Drugs@FDA / DailyMed - sermorelin (Geref) ↗· Approval and discontinuation history for the FDA-era branded product (label-derived pharmacology, half-life, adverse events).
- PubMed - sermorelin GHRH(1-29) growth hormone ↗· Primary literature on mechanism and GH/IGF-1 stimulation.
- PubMed - sermorelin elderly older adults lean body mass ↗· Small adult/elderly studies on IGF-1, lean mass, skin thickness, sleep, libido; underpowered and mostly open-label.
- PubMed - GHRH slow wave sleep humans ↗· Controlled human evidence that GHRH/GH enhances slow-wave sleep, basis for the sleep reports.
- ClinicalTrials.gov - sermorelin ↗· Trial registry; shows the limited, mostly older/diagnostic trial footprint and absence of large adult anti-aging RCTs.
- Growth hormone secretagogues: history, mechanism, clinical development (Ishida et al., 2020) ↗· Review placing sermorelin in the GH-secretagogue landscape and its development arc.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.